Skip to main content
. 2019 Nov 19;146(1):53–66. doi: 10.1007/s00432-019-03082-z

Table 2.

Correlation of the densities of myeloperoxidase-immunoreactive tumor-associated neutrophils dichotomized into quartile 1 vs. quartile 2–4 with clinicopathological patient characteristics. (1) Fisher’s exact test. (2) Kendall’s tau test. (3) Log-rank test

Total Mucosa Tumor surface Tumor center Invasion front
Q1 Q234 Q1 Q234 Q1 Q234 Q1 Q234
Valid/missing value Valid Valid Valid Valid
n/n (%) n (%) n (%) n (%) n (%) n (%) n
n
(%) n
n
(%) n (%)
Gender n p value(1) 449/0 257 0.242 358 0.899 449 0.071 386 0.013
 Female 164 (36.5) 30 (28.8) 74 (71.2) 31 (24.2) 97 (75.8) 49 (29.9) 115 (70.1) 43 (32.8) 88 (67.2)
  Male 285 (63.5) 34 (22.2) 119 (77.8) 58 (25.2) 172 (74.8) 63 (22.1) 222 (77.9) 53 (20.8) 202 (79.2)
Age group n p value(1) 449/0 257 0.774 358 0.142 449 0.744 386 0.906
 < 68 years 221 (49.2) 32 (24.1) 101 (75.9) 49 (28.7) 122 (71.3) 57 (25.8) 164 (74.2) 46 (24.5) 142 (75.5)
 ≥ 68 years 228 (50.8) 32 (25.8) 92 (74.2) 40 (21.4) 147 (78.6) 55 (24.1) 173 (75.9) 50 (25.3) 148 (74.7)
Localisation n p value(1) 440/9 250 1.0 350 0.794 440 0.639 378 0.063
 Proximal stomach 143 (31.8) 20 (26.0) 57 (74.0) 30 (26.1) 85 (73.9) 38 (26.6) 105 (73.4) 25 (19.5) 103 (80.5)
 Distal stomach 297 (66.1) 44 (25.4) 129 (74.6) 58 (24.7) 177 (75.3) 72 (24.2) 225 (75.8) 71 (28.4) 179 (71.6)
Laurén type n p value(1) 449/0 257 0.516 358 0.493 449 <0.001* 386 <0.001*
 Intestinal 239 (53.2) 29 (22.7) 99 (77.3) 50 (25.0) 150 (75.0) 42 (17.6) 197 (82.4) 34 (15.3) 188 (84.7)
 Diffuse 136 (30.3) 24 (27.9) 62 (72.1) 28 (28.0) 72 (72.0) 54 (39.7) 82 (60.3) 51 (54.3) 43 (45.7)
 Mixed 29 (6.5) 6 (35.3) 11 (64.7) 3 (12.5) 21 (87.5) 7 (24.1) 22 (75.9) 7 (26.9) 19 (73.1)
 Unclassified 45 (10.0) 5 (19.2) 21 (80.8) 8 (23.5) 26 (76.5) 9 (20.0) 36 (80.0) 4 (9.1) 40 (90.9)
T-category n p value(2) 449/0 257 0.127 358 0.082 449 0.063 386 0.017
 T1a/b 52 (11.6) 7 (17.9) 32 (82.1) 9 (20.5) 35 (79.5) 7 (13.5) 45 (86.5) 8 (15.7) 43 (84.3)
 T2 53 (11.8) 10 (27.8) 26 (72.2) 10 (20.8) 38 (79.2) 12 (22.6) 41 (77.4) 8 (15.7) 43 (84.3)
 T3 185 (41.2) 21 (20.8) 80 (79.2) 34 (22.8) 115 (77.2) 48 (25.9) 137 (74.1) 43 (26.7) 118 (73.3)
 T4a/b 159 (35.4) 26 (32.1) 55 (67.9) 36 (30.8) 81 (69.2) 45 (28.3) 114 (71.7) 37 (30.1) 86 (69.9)
N-category n p value(2) 449/0 257 0.011 358 0.468 449 0.174 386 0.751
 N0 126 (28.1) 16 (19.5) 66 (80.5) 23 (22.1) 81 (77.9) 26 (20.6) 100 (79.4) 25 (21.2) 93 (78.8)
 N1 67 (14.9) 9 (20.0) 36 (80.0) 16 (29.6) 38 (70.4) 18 (26.9) 49 (73.1) 16 (29.6) 38 (70.4)
 N2 78 (17.4) 7 (16.3) 36 (83.7) 11 (19.3) 46 (80.7) 18 (23.1) 60 (76.9) 20 (30.3) 46 (69.7)
 N3a/b 178 (39.6) 32 (36.8) 55 (63.2) 39 (27.3) 104 (72.7) 50 (28.1) 128 (71.9) 35 (23.6) 113 (76.4)
M-category n p value(1) 449/0 257 0.575 358 0.871 449 0.486 386 0.202
 M0 364 (81.1) 51 (24.2) 160 (75.8) 73 (24.6) 224 (75.4) 88 (24.2) 276 (75.8) 76 (23.5) 247 (76.5)
 M1 85 (18.9) 13 (28.3) 33 (71.7) 16 (26.2) 45 (73.8) 24 (28.2) 61 (71.8) 20 (31.7) 43 (68.3)
UICC stage 8th eds. n p value(2) 449/0 257 0.195 358 0.482 449 0.118 386 0.115
 IA/B 74 (16.5) 11 (20.8) 42 (79.2) 13 (20.3) 51 (79.7) 12 (16.2) 62 (83.8) 13 (18.1) 59 (81.9)
 IIA/B 101 (22.5) 13 (20.3) 51 (79.7) 21 (25.6) 61 (74.4) 26 (25.7) 75 (74.3) 23 (25.6) 67 (74.4)
 IIIA/B/C 189 (42.1) 27 (28.7) 67 (71.3) 39 (25.8) 112 (74.2) 50 (26.5) 139 (73.5) 40 (24.8) 121 (75.2)
 IV 85 (18.9) 13 (28.3) 33 (71.7) 16 (26.2) 45 (73.8) 24 (28.2) 61 (71.8) 20 (31.7) 43 (68.3)
Total Mucosa Tumor surface Tumor center Invasion front
Q1 Q234 Q1 Q234 Q1 Q234 Q1 Q234
Valid/missing value Valid Valid Valid Valid
n/n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Lymph node ratio n p value(1) 449/0 257 0.006 358 0.328 449 0.326 386 0.906
 < 0.189 220 (49.0) 26 (18.2) 117 (81.8) 40 (22.3) 139 (77.7) 50 (22.7) 170 (77.3) 49 (25.3) 145 (74.7)
 ≥ 0.189 229 (51.0) 38 (33.3) 76 (66.7) 49 (27.4) 130 (72.6) 62 (27.1) 167 (72.9) 47 (24.5) 145 (75.5)
L-category n p value(1) 423/26 242 0.106 338 0.528 423 0.824 365 0.904
 L0 202 (45.0) 26 (20.8) 99 (79.2) 37 (22.8) 125 (77.2) 50 (24.8) 152 (75.2) 44 (24.9) 133 (75.1)
 L1 221 (49.2) 35 (29.9) 82 (70.1) 46 (26.1) 130 (73.9) 57 (25.8) 164 (74.2) 48 (25.5) 140 (74.5)
V-category n p value(1) 422/27 241 0.146 336 0.409 422 0.860 365 1.0
 V0 374 (83.3) 58 (26.7) 159 (73.3) 70 (23.3) 230 (76.7) 95 (25.4) 279 (74.6) 82 (25.4) 241 (74.6)
 V1 48 (10.7) 3 (12.5) 21 (87.5) 11 (30.6) 25 (69.4) 11 (22.9) 37 (77.1) 11 (26.2) 31 (73.8)
Tumor grade n p value(1) 447/2 256 0.395 358 0.577 447 0.001* 384 0.008
 G1/2 108 (24.1) 12 (19.7) 49 (80.3) 25 (27.2) 67 (72.8) 14 (13.0) 94 (87.0) 16 (15.2) 89 (84.8)
 G3/G4 339 (75.5) 51 (26.2) 144 (73.8) 64 (24.1) 202 (75.9) 96 (28.3) 243 (71.7) 79 (28.3) 200 (71.7)
Resection status n p value(1) 436/13 248 0.109 348 0.694 436 0.503 374 0.717
 R0 382 (85.1) 51 (23.3) 168 (76.7) 78 (25.2) 231 (74.8) 96 (25.1) 286 (74.9) 83 (25.2) 247 (74.8)
 R1/R2 54 (12.0) 11 (37.9) 18 (62.1) 8 (20.5) 31 (79.5) 11 (20.4) 43 (79.6) 12 (27.3) 32 (72.7)
H. pylori status n p value(1) 379/70 231 0.548 302 0.723 379 0.106 332 0.612
 Negative 320 (71.3) 50 (26.2) 141 (73.8) 57 (23.0) 191 (77.0) 88 (27.5) 232 (72.5) 71 (25.6) 206 (74.4)
 Positive 59 (13.1) 8 (20.0) 32 (80.0) 14 (25.9) 40 (74.1) 10 (16.9) 49 (83.1) 12 (21.8) 43 (78.2)
EBV status n p value(1) 438/11 250 0.368 351 0.397 438 0.022 375 0.009
 Negative 416 (92.7) 61 (26.0) 174 (74.0) 79 (23.7) 254 (76.3) 108 (26.0) 308 (74.0) 93 (26.1) 264 (73.9)
 Positive 22 (4.9) 2 (13.3) 13 (86.7) 6 (33.3) 12 (66.7) 1 (4.5) 21 (95.5) 0 (0.0) 18 (100.0)
MSI status n p-value(1) 437/12 249 0.009 352 0.813 437 0.035 375 0.002*
 MSS 405 (90.2) 63 (27.3) 168 (72.7) 79 (24.2) 247 (75.8) 105 (25.9) 300 (74.1) 92 (26.7) 252 (73.3)
 MSI 32 (7.1) 0 (0.0) 18 (100.0) 7 (26.9) 19 (73.1) 3 (9.4) 29 (90.6) 1 (3.2) 30 (96.8)
HER2 status n p value(1) 412/37 232 0.788 329 0.082 412 0.066 352 0.006
 Negative 376 (83.7) 53 (25.0) 159 (75.0) 68 (22.9) 229 (77.1) 98 (26.1) 278 (73.9) 87 (27.4) 231 (72.6)
 Positive 36 (8.0) 4 (20.0) 16 (80.0) 12 (37.5) 20 (62.5) 4 (11.1) 32 (88.9) 2 (5.9) 32 (94.1)
MET status n p value(1) 440/9 253 0.408 351 0.808 440 0.665 378 1.0
 Negative 409 (91.1) 58 (24.7) 177 (75.3) 82 (25.1) 245 (74.9) 102 (24.9) 307 (75.1) 86 (24.3) 268 (75.7)
 Positive 31 (6.9) 6 (33.3) 12 (66.7) 5 (20.8) 19 (79.2) 6 (19.4) 25 (80.6) 6 (25.0) 18 (75.0)
OSS [months] p value(3) 0.052 0.134 0.142 0.017
 Total/Events/Censored 433/341/92 60/50/10 186/139/47 88/70/18 258/204/54 109/88/21 324/253/71 92/75/17 278/207/71
 Median Survival 15.0 ± 1.2 14.0 ± 2.6 18.8 ± 2.3 13.2 ± 2.1 16.7 ± 1.4 12.9 ± 1.6 16.0 ± 1.4 13.6 ± 2.2 16.7 ± 1.9
 95% C.I. 12.7–17.3 8.9–19.1 14.2–23.3 9.1–17.4 13.9–19.5 9.7–16.2 13.2–18.8 9.3–17.9 13.0–20.4
TSS [months] p value(3) 0.073 0.156 0.137 0.013
 Total/Events/Censored 405/280/125 49/35/14 179/111/68 84/60/24 238/161/77 103/75/28 302/205/97 87/65/22 260/164/96
 Median Survival 16.7 ± 1.5 13.2 ± 3.8 22.6 ± 2.5 14.6 ± 3.5 18.0 ± 2.2 14.2 ± 2.0 17.9 ± 2.6 14.7 ± 2.9 19.6 ± 3.8
  95% C.I. 13.7–19.7 5.7–20.7 17.6–27.6 7.8–21.4 13.6–22.3 10.2–18.1 12.8–23.1 9.0–20.4 12.2–27.0

(1) Fisher’s exact test, (2) Kendall’s tau test, (3) Log-rank test, * Significant after FDR-Control